



Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

Project Name: Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, a randomized, double-blind, multicenter clinical trial

Project Description: This trial is a prospective, randomized, double-blind, multicenter trial with the primary null hypothesis that, in patients with TIA or minor ischemic stroke treated with aspirin 50-325 mg/day, there is no difference in the event-free survival at 90 days in those treated with clopidogrel (600 mg loading dose then 75 mg/day) compared to placebo when therapy is initiated within 12 hours of onset.

Project Period Oct. 2009 – Sep. 2016

Funding Source: National Institute of Health / National Institute for Neurological Disorders and Stroke (NIH / NINDS) [1U01S062835-01A1](#)

Principal Investigators: S. Claiborne Johnston, MD, PhD, PI
Professor of Neurology and Epidemiology
University of California San Francisco

J. Donald Easton, MD, Co-PI
Clinical Professor of Neurology
University of California San Francisco

Description of DCU Responsibilities: DCU is a Statistical and Data Management Center (SDMC), which provides statistical design and analysis, data management and IS infrastructure.